IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 370 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed11756    
    Printed250    
    Emailed19    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2003  |  Volume : 69  |  Issue : 2  |  Page : 154--158

Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis


1 Dept. of Dermatology, AIMS, New Delhi - 110 029, India
2 Dept. of Microbiology, AIMS, New Delhi - 110 029, India
3 Dept. of Laboratory Medicine, AIMS, New Delhi - 110 029, India
4 Medical & Research Division, Cipla Ltd. Mumbai, India

Correspondence Address:
M Ramam
Dept. of Dermatology, AIMS, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17642865

Rights and PermissionsRights and Permissions

Butenafine is a new antifungal agent similar to allyl amine antifungals. A randomized controlled trial was conducted in 75 patients to compare its efficacy with clotrimazole in tinea cruris and corporis that was diagnosed on clinical features and demonstration of hyphae in a potassium hydroxide (KOH) preparation. Twenty patients treated with butenafine once daily for 2 weeks and 20 treated with clotrimazole twice daily for 4 weeks were analysed. At the end of treatment, 2 weeks and 4 weeks later, the KOH preparation was negative in 90.9%, 95.5% and 90.9% of patients respectively in the butenafine group and 100%, 96.4% and 92.85% respectively in the clotrimazole group. There was a reduction of 81.5% in the sign and symptom score at 4 weeks following treatment in the butenafine group and 85.93% in the clotrimazole group. There was no statistically significant difference between the two groups. Adverse effects were mild in both groups and did not require discontinuation of therapy except one patient treated with clotrimazole who developed dermatitis at the site of application. Butenafine appears to be as effective as clotrimazole in the treatment of tines cruris and corporis while requiring a single daily application for a shorter of 2 weeks.






[FULL TEXT] [PDF Not available]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow